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1. Introduction  
The ability of the brain to process information relies on its control of the conduction of 
electric currents. Brain diseases invariably affect this capability. One of the therapeutic 
approaches to a variety of neurological disorders therefore includes the application of 
electric currents and fields to the brain. A successful example of this strategy is the 
introduction of deep brain stimulation which has become a cornerstone of the therapy of 
advanced Parkinson’s disease (PD), dystonia and essential tremor. Several studies have 
proven its effectiveness and often patients respond immediately to this therapy. 
Invasiveness and complexity of this treatment restrict its indication. On the other hand, 
there are techniques for the non-invasive modulation of cortical excitability namely 
transcranial magnetic stimulation (TMS) as well as transcranial direct current stimulation 
(tDCS). These techniques have been investigated in several studies including patients with 
PD. However results so far are heterogeneous and limit their therapeutic value. In the 
following chapter the basic principles of as well as therapeutic experiences with invasive 
and non-invasive electrical stimulation techniques and their applications in patients with PD 
will be discussed.  
2. Electrical stimulation in Parkinson’s disease 
2.1 Invasive electrical stimulation in Parkinson’s disease 
In the modern era of medicine the modification of cerebral function by electrical 
stimulation for therapeutic purposes was considerably influenced by the introduction of 
stereotactic methods into neurosurgery in the middle of the 20th century (Hariz et al., 
2010). The stereotactic induction of lesions in the medial nucleus of the thalamus (medial 
thalamotomy) was reported in a first series with psychiatric patients “in order to reduce 
the emotional reactivity by a procedure much less drastic than frontal lobotomy” (Spiegel 
et al., 1947). The frontal lobotomy which was a psychosurgical treatment for psychoses at 
that time was associated with significant irreversible cerebral destruction. Therefore, 
applying thermocoagulation with a wire or cannula inserted stereotactically through the 
intact dura to induce a defined lesion within a distinct cerebral structure in patients with 
psychiatric disorders revealed a significant therapeutic advancement. Simultaneously, the 
potential of this technique for the treatment of movement disorders or pain syndromes 
was suggested (Spiegel et al., 1947). Indeed, the first pallidotomies performed at that time 
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had morbidity rates of 45% and a mortality rate of 15% (Gildenberg P.L., 2003). 
Stereotactically implanted intracranial electrodes offered the opportunity not only to 
induce a structural lesion by thermocoagulation but also to identify the basal ganglia 
electrographically by its distinct pattern of recordable neuronal activity. A related 
approach without the use of stereotactic instruments but with a similar technique was 
named chemopallidectomy and consisted in the instillation of absolute alcohol in the 
globus pallidus with an intracranial cannula. Reduction of rigidity or tremor in several 
geriatric parkinsonian patients who were considered to old for the alternative and 
complex anterior choroidal artery occlusion provided evidence for the potential of 
surgically targeting the basal ganglia for the treatment of movement disorders (Cooper 
I.S., 1955). Intracranial intraoperative electrical stimulation of the inserted electrodes was 
conducted early on in order to thereby identify potential targets for the induction of a 
lesion. Stimulation was performed with low (~ <30 Hz) and high (~ >30 Hz) frequencies 
in different centers at that time and a significant therapeutic effect of high frequency 
stimulation at 100 Hz with intracranial stimulation has been described in the early phase 
of this new therapy (Gildenberg P.L., 2003). Still, even though electrodes were left in place 
intracranially up to several days electrical stimulation was applied for diagnostic and not 
for therapeutic purposes. With the introduction of levo-dopa for the treatment of PD its 
surgical therapy became infrequent. In the following years intracranial electrical 
stimulation was tested as experimental procedure for a variety of disorders e.g. as a 
treatment for refractory pain or with cerebellar implants for the treatment of epilepsy (Gol 
A.,  1967; Shealy et al., 1967; Cooper et al., 1976). Devices for chronic subdural electrical 
stimulation were developed within the same time. The idea of chronically implanted 
subdural electrodes on the visual cortex working as “prosthesis” for the blind by inducing 
meaningful visual perceptions in blind patients by electrocortical stimulation was realized 
in a few patients (Brindley G.S. and Lewin W.S., 1968). Still, this method was not 
implemented in larger groups of patients for a variety of reasons. Also, early promising 
results of therapeutic deep brain stimulation in epilepsy or pain could not be reproduced 
by following studies leading to a subsequent decline of deep brain stimulation in 
epilepsy. In succession torticollis spasmodicus appears to be the first disorder of the 
motor system that has been treated with chronic electrical stimulation of the spinal cord 
(Gildenberg P.L., 1977). Then, in the 1980s the group of Benabid and colleagues 
rediscovered the beneficial therapeutic effect of intracranial electrical stimulation. Their 
report of the suppression of parkinsonian and non-parkinsonian tremor when stimulating 
the nucleus ventralis intermedius of the thalamus (VIM) intraoperatively before VIM 
thalamotomy as well as the first description of permanent implantation of deep brain 
stimulators into the VIM in four patients pioneered the surgical treatment of PD by deep 
brain stimulation as applied today (Benabid et al. 1987).  
2.1.1 The object of invasive electrical stimulation in Parkinson’s disease 
The important role of the basal ganglia for movement control has probably been 
recognized in the 17th century (Lanska D.J., 2010). Modern concepts of function of the 
basal ganglia have lead to and benefit from the introduction of neurosurgical approaches 
in the therapy of movement disorders like PD. The basal ganglia include the striatum 
(putamen and caudate nucleus), the globus pallidus internus (GPi), the globus pallidus 
externus (GPe), the subthalamic nucleus (STN), the subtantia nigra pars reticularis (SNr) 
and the substantia nigra pars compacta (SNc). The basal ganglia receive their main 
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external input from the primary motor cortex (M1), premotor areas including the 
supplementary sensorimotor area (SSMA) and the cingulate motor area in the anterior 
cingulum. Additionally, the ventrolateral and the ventral anterior nuclei of the thalamus 
project to the basal ganglia. The striatum is the first relay and therefore the main gate for a 
majority of the afferents to the basal ganglia. Also the STN receives primary afferents 
from the aforementioned cortical areas (Table 1). Importantly, the projections to the basal 
ganglia are highly organized by means of their functional and topographic origin into 
three main groups of afferents (Parent A., 1990). First, afferents from M1 and premotor 
areas including the SSMA preferentially project to the postcommissural putamen; second, 
afferents from prefrontal cortex project to the precommissural putamen and the caudate 
nucleus; third, those afferents originating in limbic areas including the anterior cingulum 
and the orbitofrontal cortex project primarily to the ventral striatum. Additionally, 
afferents from the primary motor regions are organized somatotopically including distal 
limb projections (Bauswein et al., 1989). This organizational principle of afferents has been 
recognized in the striatum as well as in the STN whose dorsolateral part receives 
information from M1, while its ventrolateral part receives projections from the caudal 
cingulate motor area. The SSMA and the pre-SSMA as well as the rostral part of the 
cingulate motor area project to the dorsomedial part of the STN, while other premotor 
areas connect to its ventromedial part (Hartmann-von Monakow et al., 1978; Takada et al., 
2001). Electrophysiological studies in non-human primates revealed that corticostriatal 
neurons differ in their neurophysiological properties from corticospinal neurons. The 
former show slower conduction velocities, lower discharge rates and a different response 
pattern to somatosensory input. Indeed, both systems appear to be supplied by 
completely different populations of cortical neurons (Turner and DeLong, 2000). Another 
important source of input to the striatum are mesencephalic nuclei with the dopamiergic 
projections of the SNc being the most significant. The SNc is itself influenced by feedback 
projections from the STN, the SNr and external afferent sources like the prefrontal and 
orbitofrontal cortex, the raphe nuclei, the superior colliculi. Functionally, a tonic firing 
pattern that can be modified by reward-learning has been recognized as a characteristic 
electrophysiological pattern of dopaminergic neurons of the SNc (Hollerman & Schultz, 
1998, Wichmann and DeLong, 2007).  
On a cellular level afferents to the striatum terminate almost exclusively on medium spiny 
neurons that represent 90-95% of all striatal neurons. The information processing within 
these GABAergic neurons is further modulated by intrinsic cholinergic and peptidergic 
interneurons (Wichmann and DeLong, 2007). The large majority of target-neurons in the 
STN is glutamatergic unlike all other nuclei of the basal ganglia and only few neurons in the 
human STN were found to be GABAergic (Levesque and Parent, 2005). The information is 
further processed via two different systems: the direct and indirect pathway. The former 
projects directly to the output nuclei of the basal ganglia, the GPi and the SNr. The indirect 
pathway is polysynaptic and its information is modulated in the GPe and STN from where 
it then projects to GPi and SNr as well. Medium spiny neurons forming the direct pathway 
preferentially exhibit dopamine D1-receptors and express substance P. Indirect pathway 
medium spiny neurons on the contrary do express predominantly D2-receptors and 
enkephalin (Gerfen et al., 1990). Therefore, both major classes of dopamine receptors - the 
D1-like family whose activation increases and the D2-like family whose activation decreases 
the concentration of the second messenger cyclic adenosine monophosphate (cAMP) - are 
represented in the striatofugal system. The dopaminergic projections from the SNc balance 
direct and indirect striatal projections within the basal ganglia, the net effect of which 
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promotes an inhibitory influence on the output of the basal ganglia to the thalamus leading 
to increased thalamocortical activity in case of the direct pathway and to an opposite effect 
in case of the indirect pathway (Wichman and DeLong, 2007). Loss of function of the 
neurons of the SNc in Parkinson’s disease causes a functional imbalance of the output of the 
basal ganglia.  
The output of the basal ganglia that arises mainly from the GPi and SNr is primarily 
directed towards the ventral anterior nucleus and the ventrolateral nucleus of the thalamus. 
From this nucleus the information is further transmitted to motor-, premotor- and prefrontal 
cortex (Hoover and Strick, 1993). As mentioned previously the relative topographic 
segregation between the three main functional input systems of the basal ganglia is 
maintained through the different stages of information processing including its output 
projections (Shink et al., 1996). Other neurons of the SNr project to the superior colliculus or 
the reticular formation.  
While the aforementioned subcortical network maintains normal motor function in the 
healthy state its dysfunction in Parkinson’s disease is correlate of the clinical symptoms like 
tremor, hypokinesia, rigidity. The depletion of dopamine in the striatum due to 
degeneration of the SNc is decisive in this pathophysiology and both the dysinhibition of 
the direct pathway as well as the increased inhibitory activity of the striatopallidal fibers of 
the indirect pathway finally lead to a reduced activity of thalamocortical projections to the 
various motor areas. Aside from the pure imbalance of inhibitory and excitatory 
mechanisms in PD recent research has recognized alterations in frequency and 
synchronization of basal ganglia circuits (Hammond et al., 2007). Some evidence suggests 
that increased synchronization of oscillations in the beta-frequency range between basal 
ganglia and cortical projection areas impair movement control and are a correlate of PD. 
This synchronization indeed can be suppressed by dopaminergic therapy. Further research 
on this subject is required. 
 
Anatomical 
structure 
Main 
transmitter 
Striatum GABA 
STN Glutamate 
GPi GABA 
GPe GABA 
SNc Dopamine 
SNr GABA 
Table 1. This table lists the predominant neurotransmitters of substructures of the basal 
ganglia. STN = subthalamic nucleus, GPi = globus pallidus internus, GPe = globus pallidus 
externus, SNc = substantia nigra pars compacta, SNr = substantia nigra pars reticulata. 
GABA = gamma-amino-butyric acid. 
2.1.2 The medium of invasive electrical stimulation in Parkinson’s disease 
Currently, the hardware implanted for deep brain stimulation includes the stimulation 
device or internal pulse generator, the stimulating electrode(s) and a connector between 
these elements. The battery driven stimulator is usually implanted subcutaneously in the 
subclavicular area. This device is connected to two or less often one deep brain 
electrode(s) by a stimulator cable that is tunneled through cervical, retroauricular and 
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cranial subcutaneous tissue. The deep brain electrodes have four electrode contacts at 
their tip counting from the most central electrode contact that is labeled as contact zero. 
The diameter of the lead body is 1.27 mm. The length of the electrode contact varies 
between 1.5 and 3 mm whereas the electrode spacing varies between 0.5 and 4 mm 
depending on the model of the lead. This system is controlled by an external telemetric 
programmer that allows to modify current intensity, pulse width, frequency of 
stimulation, polarity of the stimulus and electrode configuration. A typical type of deep 
brain stimulator offers a range of 0 - 25.5 mA in the current mode or 0 - 10.5 V in the 
voltage mode regarding adjustment of the stimulation intensity. The frequency of 
stimulation can be modified within a range of 2-250 Hz and the pulse width can be 
altered between 60 and 450 µs according to the manufacturer of deep brain stimulation 
devices (Medtronic; Minnesota, U.S.A.). However, the parameters stimulation frequency 
as well as pulse width are infrequently subject to changes and the fine tuning of the 
stimulator is commonly done by changing the stimulus intensity. Stimulation frequency 
is most often set at around 130 Hz providing a good ratio between efficiency and energy 
consumption (Volkmann et al., 2006). This is based on studies which demonstrated a 
high efficiency of electrical stimulation within a range of stimulation frequencies 
between 30 and 250 Hz when stimulation intensity is left constant (Mihailovic and 
Delgado, 1956). Similarly the range in which the pulse width can be varied closely 
reflects the most efficient and safest interval for neuronal excitation which is between 100 
and 500 µs (Mihailovic and Delgado, 1956). In general and due to different time 
constants a shorter pulse width is more likely to excite axons or axon hillocks at least in 
the case of single pulse stimulation (Ranck, 1975; Nowak and Bullier, 1998). And 
commonly the pulse width of a deep brain stimulator is set at 60 µs (Perlmutter and 
Mink, 2006). In contrast to these parameters, the configuration and polarity of the 
electrodes are typically modified in the course of the treatment. A monopolar montage 
with a single “active” cathodal electrode contact on the deep brain electrode referenced 
to the “inactive” anodal pulse generator or a bipolar montage between two of the four 
electrode contacts with one serving as cathode and one as anode can be chosen. The 
monopolar configuration with an inactive reference is often preferred since it improves 
the ability to relate a therapeutic effect to a specific electrode contact. Nonetheless, 
monopolar as well as bipolar stimulation should both be regarded as being relatively 
focal. The preference of the cathodal polarity for monopolar stimulation results from its 
higher efficiency in stimulating neurons compared to anodal pulses regarding 
intracerebral application of electrical stimulation. Indeed, threshold currents for the 
induction of action potentials in pyramidal tract cells can differ up to more than factor 
ten between cathodal and anodal current (Stoney et al., 1968). Neuroanatomically 
electrical stimulation preferentially activates structures parallel to the electrical field 
(Ranck, 1975). Knowledge of this factor may help to interpret the effects of DBS. DBS in 
PD is continuous and therefore energy consuming. Optimal parameters of DBS account 
for this factor increasing the interval for exchange of the battery. In fact, modern devices 
are advertised with having a longevity of 9 years (Medtronic; Minnesota, U.S.A.). 
However, patients need to be aware of the potential necessity of a second surgical 
intervention for battery changes. Also the existence of intracranial metallic material as 
well as the stimulation device impose vigilance on the possible hazards and restrict use 
of magnetic resonance imaging (MRI), transcranial magnetic stimulation (TMS), 
diathermia or other external electromagnetic sources in patients with DBS. 
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2.1.3 The mechanism of action of invasive stimulation in Parkinson’s disease 
The choice of the target to be stimulated in order to reduce symptoms of PD has been 
decisively influenced by previous experiences with lesional surgery for the therapy of PD. In 
fact Benabid et al. (2009) stated that “DBS mimics the effects of ablation in all targets used to 
date.” However, dependence on active stimulation of the electrode contacts clearly indicates 
a dynamic neurophysiologic mechanism of action of DBS which has not been fully 
elucidated so far (Perlmutter and Mink, 2006). The similarities between the effects of a lesion 
and stimulation of particular neuroanatomical targets supported the theory that high-
frequency deep brain stimulation of the STN and other targets acts in general inhibitory on 
the neuron and hence on the functional output of the stimulated structure i.e. of the STN. In 
accordance with that hypothesis a study using single neuron patch-clamp-technique in 
prepared slices of the STN of Wistar rats has shown that electrical high-frequency 
stimulation (stimulation frequency = 100-250 Hz, pulse width = 100 µs, duration of 
stimulation = 60 seconds) is able to block single-spiking or bursting activity of STN-neurons 
for about six minutes after stimulation an effect that can be evoked repeatedly (Beurrier et 
al., 2001). This effect did neither depend on Ca2+ mediated transmitter release nor was it the 
consequence of membrane hyperpolarization. In another study using in-vivo records of 
patients undergoing surgery for advanced PD single pulses with an intensity of 50 µA 
induced short-lasting inhibition of tonically firing neurons of the GPi within a radius of up 
to more than 600 µm. In this study however, a transmitter-dependent mechanism was 
proposed (Dostrovsky et al., 2000). Moreover, it was demonstrated in a Positron-emission-
tomography (PET)-study that the regional cerebral blood flow (rCBF) of the SSMA, the 
cingulate motor cortex and the dorsolateral prefrontal cortex (DLPFC) during active 
stimulation of the STN is significantly increased compared to inactive stimulation. These 
findings resembled the results of studies which compared changes of rCBF before and after 
pallidotomy (Grafton et al., 1995; Limousin et al., 1997). Also, it was shown by PET that the 
pathophysiological hypoactivity of the SSMA as found in PD is reversed by active DBS of 
the STN as well as pallidotomy (Ceballos-Bauman A.O., 2003). Nevertheless, the view of a 
predominant inhibitory action of DBS has been challenged for several reasons (Vitek J.L., 
2002). Importantly, other studies focused on the effects that DBS of the STN exerts on related 
nuclei of the basal ganglia. Supporting increased excitatory action of the STN elevated levels 
of glutamate were found in SNr and GP of normal rats after DBS of the STN with 
intracerebral microdialysis (Windels et al., 2003). This effect depended strongly on the 
frequency of stimulation with a maximum increase of glutamate in the GP and SNr at 130 
Hz, weaker increases at either 60 or 350 Hz and no effect at 10 Hz being concordant with the 
well-known frequency dependence of the clinical effect of DBS of the STN in humans. 
Studies that demonstrated an increased activity of neurons in the SNr after DBS of the STN 
are in line with these results. Nonetheless, effects were depending on stimulation intensity 
and while high intensities of high-frequency DBS induced the aforementioned increase in 
neuronal activity, low-stimulation intensity reversed this effect (Maurice et al., 2003). In light 
of the evidence suggesting blocking of activity of STN neurons it is likely that the excitation 
measured in related nuclei is due to activation of efferent fibers from the STN rather than 
the neurons themselves. Experimental evidence suggest that the threshold for activation by 
intracranial electrical stimulation is lowest at axons and their initial segments and in fact 
much higher at the neuronal cell body (Nowak and Bullier, 1998). Another effect of 
intracerebral brain stimulation may be relevant for the efficacy of this treatment which is the 
“anodal surround” effect. With increasing intensity of cathodal DBS the depolarizing 
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outward current induced by the stimulation around the electrode is compensated by an 
increasing hyperpolarizing inward current which is highest in relative proximity to the 
current source hence resembling the effect of anodal stimulation. Therefore, conduction of 
action potentials of an excited axon may be blocked completely in orhodromic and 
antidromic direction. With greater distance from the electrode contact the anodal-like effect 
decreases and action potentials will not be interrupted (Ranck, 1975). Consequently, action 
potentials of those elements centered closest around the stimulating electrode contact may 
not leave this zone around the contact further supporting a theory of central inhibition and 
peripheral excitation. An influence of DBS on oscillations and firing patterns in the basal 
ganglia has been proposed as relevant correlate of its therapeutic efficiency more recently 
(Welter et al., 2004). 
2.1.4 The indication for invasive electrical stimulation in Parkinson’s disease 
Despite its invasive nature, the perioperative risk and the highly specialized therapy DBS 
offers some advantages over the classical pharmacological treatment of PD that hold true 
regardless of the stage of the disease. DBS acts continuously reducing fluctuation of 
symptoms that often are due to variable serum levels of antiparkinsonian drugs. Therefore, 
if implantation succeeded DBS has a good therapeutic predictability. Also, psychiatric side-
effects like hallucinations due to levo-dopa administration or use of dopaminergic drugs are 
less common with DBS. However, the therapeutic value of DBS depends to a significant 
extent on the correct identification of appropriate patients for this therapy. Since other 
parkinsonian syndromes do not respond sufficiently to DBS the diagnosis of an idiopathic 
Parkinson syndrome (IPS) or PD must be firm. Criteria for the adequacy of the diagnosis of 
PD have to be checked before indicating a surgical approach in the treatment of PD. An 
asymmetric onset of the disease and early and satisfying response to levo-dopa are typical 
and crucial features of PD. Also tremor is typical of PD whereas it is infrequent in other 
parkinsonian syndromes. On the other hand early existence of significant postural 
instability, autonomic dysfunction or cognitive decline point to an atypical Parkinson 
syndrome. In any case the presurgical evaluation must include the performance of a levo-
dopa-test (Charles et al., 2002). A single high-dose application of levo-dopa e.g. 250 mg 12 
hours after discontinuation of antiparkinsonian treatment is sufficient. The motor symptoms 
of PD then should be evaluated in the state off medication and in the best on-state or 1 hour 
after application of the single test-dose of l-dopa. Part III of the Unified Parkinson’s disease 
rating scale (UPDRS) is the preferred tool to asses the outcome of this test and an 
improvement of 30% in this part of the UPDRS is regarded as significant and typical of PD. 
However, some centers demand an even better presurgical response to this test (Welter et 
al., 2002). Since dementia should preclude surgery for DBS a neuropsychological testing is 
part of the presurgical evaluation. As a screening tool for surgery the mini-mental state 
examination (MMSE) is useful and a result of less than 24 points would omit further testing. 
However, it has to be taken into considerations that often candidate patients are not 
unfamiliar with this test and results may incorporate training effects. Age is negatively 
correlated with a favourable outcome of the procedure. Often an age of 75 is regarded as 
upper limit for performing an implantation of deep brain electrodes. Still, this guideline is 
not exclusive. A recent cranial MRI is essential for the presurgical evaluation and should 
rule out leukoencephalopathy, atrophy or other functionally relevant abnormalities. Also a 
preexisting psychiatric disorders will preclude a patient from surgery for DBS. Therefore 
patients will need to be assessed by a psychiatrist presurgically. A multidisciplinary setting 
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is required for taking the decision for implantation of a deep brain stimulator. Today, DBS is 
a treatment choice for advanced PD that is not manageable by pharmacotherapy e.g. due to 
motor fluctuations, dyskinesias or psychiatric side effects of medication. Currently, a 
multicentre randomized, open-label clinical trial is investigating a potential role of STN-DBS 
compared to best medical treatment on quality of life for earlier stages of the disease 
(NCT00354133). 
2.1.5 The outcome of invasive electrical stimulation in Parkinson’s disease 
According to the manufacturer of the medical devices for deep brain stimulation (DBS), the 
healthcare company Medtronic (Minnesota, U.S.A.), more than 80.000 patients have received 
deep brain stimulators since 1995 as of March 2011. DBS first was approved for the therapy 
of essential tremor in Europe in 1995 and in the U.S.A. in 1997. In 1998 it was licensed for 
therapy of advanced Parkinson’s disease in Europe, Canada and Australia while the 
approval of the food and drug administration (FDA) in the U.S.A. followed in 2002. An 
approval for the treatment of dystonia in the U.S.A. came in 2003. Additionally, DBS can 
now be applied for severe obsessive compulsive disorders (OCD) and focal epilepsy 
refractory to pharmaceutical treatment in Europe. 
Three structures are currently targeted for invasive therapy of PD: the nucleus ventralis 
intermedius of the thalamus (VIM), the globus pallidus internus (GPi) and the nucleus 
subthalamicus (STN). The effectiveness of electrical deep brain stimulation of these 
intracerebral structures for the therapy of PD has each been proven by several clinical 
outcome studies. Among the aforementioned target structures the VIM was the first which 
was investigated for therapy of PD (Benabid et al., 1987). Today it is the target least often 
chosen for DBS in PD. However, it remains a particularly effective therapy for resting or 
postural tremor in PD, both of which are less well controlled by the alternative strategies of 
DBS of the GPi or STN. Conversely, improvement of akinesia and rigidity is less satisfying 
with DBS of the VIM compared to DBS of STN or GPi. Hence, DBS of the VIM is a valuable 
therapeutic choice in patients with tremor dominant forms of PD and is effective in about 
90% of these patients (Tarsy et al., 2008). Also, the results of a prospective randomized study 
indicate that DBS of the VIM is superior to thalamotomy regarding clinical outcome with 
significantly higher effectiveness concerning activities of daily living and upper extremity 
mobility as well as a more favorable benefit risk ratio (Schuurman et al., 2000).  The second 
most frequently targeted structure for DBS for PD is the GPi. The motor score of the UPDRS 
improves by 30-40% on average with results ranging from 10-70% after uni- or bilateral DBS 
of the GPi as measured 3 to 12 months after surgery in most studies (Weaver et al., 2008). In 
two studies the clinical benefit of bilateral DBS of the GPi remained relatively stable in a 
long-term perspective after two and three to four years compared to short-term results after 
six and twelve months respectively indicating a long-term benefit of this treatment (Ghika et 
al., 1998; Rodriguez-Oroz et al., 2005). This improvement in motor function is reflected by 
patients self-reporting a significant increase of daily time in an on-state from 26 to 69% 
following bilateral electrode implantation in the GPi (Rodriguez-Oroz et al., 2005). The main 
target of DBS for PD today is the STN. A reduction of the motor part of the UPDRS of 50% 
on average can be expected after implantation of depth electrodes into the STN. Also, STN 
DBS is effective regarding bradykinesia, rigidity as well as tremor. Additionally, dyskinesias 
and motor fluctuations are likely to be reduced significantly. On the other hand, postural 
stability more often does not improve satisfactorily following DBS of the STN and may even 
worsen in some cases. Regarding non-motor consequences of this therapy it has been 
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suggested that a decline in cognitive abilities may be related to DBS of the STN. However, 
from current data it is not clear to which extent this finding is the consequence of the natural 
course of the disease. A decisive advantage of STN DBS is the potential postsurgical 
reduction in the levo-dopa dosis which may in a subgroup of patients even lead to a 
temporary cessation of pharmacotherapy (Merello, 2008). In general, the procedure results 
in a better quality of life for patients on average. One study compared DBS of the STN in 
addition to medication against best pharmacotherapy alone in patients with advanced PD. 
Significant superiority of the former treatment was demonstrated in both the UPDRS as well 
as in a PD quality of life scale after six month in patients under 75 years of age (Deuschl et 
al., 2006). Even though DBS does not exceed the overall effectiveness of levo-dopa therapy 
off states are less frequent with DBS. Comparison between DBS of the STN and the GPi 
based on the literature suggests that both procedures are equally effective  regarding motor 
outcome and self-reported function (Follett et al., 2010). Due to different parameters of 
stimulation battery life of stimulators of the GPi may be shorter compared to devices 
implanted for stimulation of the STN. Also, patients undergoing STN DBS require a lower 
dose of dopaminergic treatment compared to patients after GPi DBS. In contrast, 
neuropsychological complications may be less frequent with stimulation of the GPi (Weaver 
et al., 2008; Follett et al., 2010). Aside from the potential benefits of any type of DBS patients 
need to be made aware of the perioperative risks including implantation site infection or 
intracranial hemorrhage and long-term risks like breakage of material, dislocation of the 
electrodes or an immunological reaction. Finally it must be clarified to the patient that the 
procedure occasionally may fail to improve the symptoms of PD. 
2.2 Non-invasive stimulation in Parkinson’s disease 
There is good evidence from basic research that application of rTMS and tDCS can have a 
lasting impact on cortical plasticity and several studies suggest that these techniques may 
offer a new therapeutic approach to a variety of neurological disorders. Still, compared to 
DBS the therapeutic effects of transcranial stimulation in Parkinson’s disease so far appear 
to be rather small and variable. This may in part be due to a heterogeneity of study 
protocols regarding several parameters of stimulation. Representing innovative mechanisms 
exploration of the therapeutic potential of these techniques deserves further attention.  
2.2.1 Technical aspects of non-invasive electrical stimulation  
Transcranial magnetic stimulation: Current flow in an iron coil will induce a magnetic field 
perpendicular to the electric current flow. The magnetic field again induces an electric field 
perpendicular to itself. In consequence, this electric field is parallel and in opposite direction 
to the inducing current flow. When applied on the scalp above the cortex brief currents of an 
electric coil are able to produce direct excitation of neurons. While single pulse transcranial 
magnetic stimulation (TMS) is used to induce a neuronal action potential which then may 
produce a motor evoked potential the single pulses of repetitive TMS (rTMS) usually do not 
reach the threshold for inducing action potentials. Several parameters that can be 
determined with single pulse TMS reflect different aspects of cortical excitability: 1) the 
resting motor threshold (RMT) or active motor threshold (AMT) probably reflect membrane 
properties, 2) the silent period (SP) which is a quiescent phase in the electromyogram (EMG) 
is partially of cortical origin and is related to the function of GABA-B receptors. 3) short 
intracortical inhibition (SICI) and short intracortical facilitation (SICF) occur when a 
subthreshold stimulus precedes a suprathreshold stimulus by less than 5 ms or 8-30 ms 
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respectively. SICI likely depends on GABAergic function while mechanisms of the SICF are 
less clear and probably involve function of GABA receptors as well as N-methyl-D-aspartate 
(NMDA)-receptors (Hallett, 2007; Ziemann, 2004).  
On the other hand, rTMS has the potential to alter the cortical excitability depending on 
duration and mode of stimulation (Hallett, 2007). rTMS frequencies of around 1 Hz induce 
an inhibitory effect on cortical excitability (Chen et al., 1997) and rates of more than 5 Hz 
generate facilitation (Pascual-Leone et al., 1994; Hallett, 2007). Huang et al. (2005) developed 
a different high-frequency transcranial magnetic stimulation (TMS) - called Theta-burst 
stimulation (TBS) - with excitability modulating after effects of up to 60 minutes in healthy 
volunteers. Here the repetition rate of the rTMS is irregular with three pulses with an inter-
pulse interval of 20 ms (50 Hz) repeated every 200 ms (5 Hz) applied either continuously for 
40 seconds as continuous TBS (cTBS) or for two seconds repeated 20 times every 10 seconds 
then named intermittent TBS (iTBS). cTBS produces a short-lasting inhibitory effect on 
cortical excitability and iTBS induces a short-lasting cortical facilitation. This induction of 
cortical plasticity or metaplasticity resembles the effects of repetitive electrical stimuli of 
single neurons which lead to either long-term potentiation (LTP) or long-term depression 
(LTD). Hence, the effects of rTMS are often referred to as LTP-like facilitation and LTD-like 
inhibition, respectively. Therapeutic applications of rTMS is based on these facilitatory or 
inhibitory effects that outlast the stimulation procedure itself and are aimed to modulate 
excitability of the cortex at least transiently.  
Several substances were found to alter the effects of TMS on cortical excitability or rTMS on 
cortical plasticity. Based on a review by Ziemann (2004) carbamazapine, phenytoin and 
lamotrigine which all are blocking sodium-channels reduce the motor threshold. Lorazepam 
and diazepam increase the SICI while they reduce the SICF. The NMDA-receptor 
antagonists dextrometorphan and memantine also reduce the ICF while SICI is enhanced. 
This pattern is also observed in a dose-dependent manner for ethanol. And D2-agonists like 
bromocriptine or cabergoline as well as the combined D1-/D2-agonist pergolid are 
enhancers of the SICI as well while an opposite effect is observed for the dopamine-
antagonist haloperidol. Therefore dopamine receptor agonists or antagonists have been 
termed “inverse modulators of motor cortex excitability” (Ziemann et al., 1997). LTP-like 
cortical plasticity as studied mainly with paired associative stimulation (PAS) is increased 
during treatment with D2-agonist cabergoline as well as methylphenidate and decreased 
under treatment with NMDA-receptor antagonist dextrometorphan as well as haloperidol, 
lamotrigine, lorazepam and biperiden (Ziemann et al., 2006). 
Aside from medical drugs the duration of stimulation may decisively affect the result of rTMS. 
Whereas 40 seconds of continuous TBS decreases cortical excitability, halving the same 
stimulation to 20 seconds induces facilitatory effects (Gentner et al., 2008). A similar reversal of 
the impact of a stimulation has been reported by others (Gamboa et al., 2010). An additional 
influence on the effect of cortical stimulation may results from the state of pre-activation of 
target muscles during a stimulation. As an example, effects of iTBS can be abolished when the 
muscle of interest is contracted with approximately 10% of maximal power (Huang et al., 
2008). It is important to note that in PD rigidity may be more often present at rest in contrast to 
situations in most studies which are performed with healthy individuals. Pre-activation of a 
muscle e.g. due to rigidity or tremor in these patients may shift intracortical homeostasis, 
which then may influence MEP-amplitudes and neuronal recruitment. 
Transcranial direct current stimulation: In 1980 it was demonstrated that a high-voltage 
shock applied transcranially over the primary motor cortex is able to produce a motor-
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evoked potential (Merton and Morton, 1980). Despite being non-invasive the application of 
this transcranial electric stimulation (TES) is painful which limits its applicability. A well-
tolerated technique of transcranial electric stimulation has been introduced into research on 
neuroplasticity in the recent past (Nitsche and Paulus, 2000). Here instead of directly 
inducing action potentials a weak direct current is applied on the scalp and is able to 
gradually modulate cortical excitability in humans. An “active” electrode placed on the 
scalp above a cortical target region to be stimulated – e.g. above the primary motor cortex – 
and a distant reference electrode that is usually placed supraorbitally and contralaterally to 
the active electrode are both connected to a battery-driven stimulator forming an electric 
circuit. In healthy young individuals the cerebral cortex beneath a cathodal electrode can be 
hyperpolarized whereas the cortex beneath an anodal electrode can be depolarized as 
shown by decrease or increase of the amplitude of motor evoked potentials (MEPs). This 
effect can last up to 60 minutes after stimulation and even longer under circumstances 
(Nitsche et al., 2007). More recently, Terney et al. (2008) similarly showed that alternating 
current stimulation with random amplitude and frequency variation -  transcranial random 
noise stimulation (tRNS) – is able to produce a significant increase in regional motor-cortical 
excitability in healthy subjects for up to 60 minutes after the end of stimulation. Studies have 
demonstrated a relevance of different neuronal transmitter systems for the mediation of this 
effect. For example, the NMDA-receptor antagonist dextrometorphan is able to completely 
abolish the effect of either anodal or cathodal tDCS (Liebetanz et al., 2002). It has been 
shown that the decreased cortical excitability following cathodal tDCS can be prolonged by 
administration of pergolide, a combined D1/D2 agonist, and can be diminished by 
sulpiride, a D2-antagonist. Additionally, co-administration of pergolide and sulpiride 
abolishes effects of cathodal as well as anodal tDCS with a tendency of reversing effects of 
anodal stimulation (Nitsche et al., 2006). Confirmatory, it has been reported more recently 
that the facilitating effect of anodal tDCS in healthy volunteers can be reversed under the 
influence of l-dopa and may lead to a significant decrease in cortical excitability (Kuo et al., 
2008). Indeed, a complex U-shaped or inversely U-shaped dose-dependent effect of D2-
receptor stimulation on MEP-amplitudes in healthy individuals after cathodal or anodal 
tDCS respectively has been proposed (Monte-Silva et al., 2009). These results highlight 
especially the role of dopamine in cortical plasticity affecting strategies on the application of 
this technique in patients with Parkinson’s disease.  
2.2.2 Neurophysiology of non-invasive electrical stimulation in Parkinson’s disease 
Transcranial magnetic stimulation: Some of the basic parameters measured by single pulse 
or paired pulse TMS are affected by PD and medication for the disease. Typically, there is no 
change in motor threshold in patients with PD compared to healthy individuals. The silent 
period as well as the SICI are decreased and can be normalized by application of 
parkinsonian medication in patients with PD (Priori et al., 1994; Lefaucheur et al., 2004; 
Hallett, 2007). Most studies do not report a significant effect of PD on ICF (Cantello et al., 
2002). However, results regarding the effect on this parameter are heterogeneous (Bareš et 
al., 2003).  
The effects of rTMS on neurophysiologic parameters in patients with PD can significantly 
differ from those in healthy persons. Gilio et al. (2002) already described a lack of MEP-
changes after 5-Hz rTMS in patients with PD in contrast to healthy subjects. Moreover, they 
found that voluntary contraction of the target-muscle during 5 Hz rTMS did abolish changes 
in cortical excitability. Accordingly, a recent study showed that iTBS does not induce 
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cortical plasticity in patients with PD under dopaminergic medication (Stephani et al., 2011). 
Despite findings of Ueki et al. (2006) who reported a restored cortical plasticity in patients 
with PD after administration of dopaminergic drugs in response to interventional paired 
associative stimulation (iPAS) this may not be the case in response to iTBS. And in a 
placebo-controlled, double-blind, randomized trial on iTBS in patients with PD there was no 
improvement of the UPDRS after 8 sessions of stimulation over the motor cortex and 
dorsolateral prefrontal cortex (Benninger et al., 2011; table 2). Comparably, no change in 
cortical excitability after application of an inhibitory continuous TBS (cTBS) protocol could 
be found in a recent report (Eggers et al., 2010).  
Transcranial direct current stimulation: Within the few studies published on tDCS in 
patients with PD there is only one that also reports on the effects of stimulation on a 
neurophysiological parameter (Fregni et al., 2006). This study demonstrated a 70%-increase 
of the MEP-amplitude at a single time-point directly after 20 minutes of anodal tDCS over 
the primary motor cortex with an intensity of 1 mA. The same protocol with cathodal 
stimulation over the primary motor cortex induced a significant decrease of the MEP-
amplitude of around 20%. These results are analogue to those of healthy persons and 
interestingly, antiparkinsonian drugs in these patients were held for approximately 12 hours 
prior to the experiment. In a recent study a new technique of transcranial alternating current 
stimulation (tACS) termed transcranial random noise stimulation (tRNS) was applied. This 
technique uses randomly alternating currents of ± 500 µA. Patients with PD showed a 
decrease in cortical excitability in contrast to results on healthy subjects whose cortical 
excitability increased after 10 minutes of tRNS (Stephani et al., 2011; Terney et al., 2008). 
Continued dopaminergic therapy may have contributed to this paradoxic effect. 
2.2.3 Therapeutic use of non-invasive electrical stimulation in Parkinson’s disease 
Both, rTMS and tDCS offer the possibility of non-invasively altering cortical excitability and 
inducing cortical plasticity in humans (Pascual-Leone et al., 1994, Nitsche and Paulus, 2000). 
However, they share the disadvantage of not being able to directly modulate subcortical 
structures like the basal ganglia due to a restricted operating distance. Hence, their 
therapeutic potential depends on disease processes that directly or indirectly affect cortical 
function. A pathological decrease or increase in excitability of cortical areas like the 
supplementary motor area (SMA), the dorsolateral prefrontal cortex (DLPFC) and the 
primary motor cortex (M1) has been demonstrated in various stages of Parkinson’s disease 
thus providing potential targets for therapeutic applications of non-invasive stimulation in 
PD (Lefaucheur, 2005).  
Transcranial magnetic stimulation: Based on these concepts rTMS has been applied in 
patients with PD in several studies with a variety of different stimulation protocols (Table 2 
and Table 3). A meta-analysis of studies that reported on effects of rTMS on the UPDRS 
between 1985 and 2007 included 10 sufficient prospective trials with control groups on 
different sham conditions. Whereas in 6 trials high-frequency rTMS was used 3 trials 
applied low-frequency rTMS and in one trial both techniques were used. A significant effect 
size of 0.58 was only found for high-frequency rTMS whereas meta-analysis of low-
frequency rTMS revealed no therapeutic effect (Elahi et al., 2008). In the one study that 
tested 10 Hz as well as 0.5 Hz real rTMS in patients with Parkinson’s disease both were 
shown to improve motor performance 20 minutes after their application. However, their 
effects on parameters of excitability were reversed compared to healthy individuals 
indicating an altered motor cortex excitability in these patients (Lefaucheur et al., 2004). 
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Improvement in the UPDRS has been reported after low and high-frequency rTMS of 
varying duration and location by others (Wu et al., 2008). However, the largest study of 
rTMS in PD so far had 85 participants that were assigned to three different groups. 
Applying very low frequency rTMS (0.2 Hz) there was no improvement of UPDRS III 
(Okabe et al., 2003). In an early study Siebner et al. (2000) e.g. detected a significantly 
improved mobility of the arm one hour after 5 Hz rTMS over the contralateral M1 area of 
the hand. Favouring the effectiveness of high-frequency rTMS, Strafella et al. (2001) could 
show that 10 Hz rTMS for one second every 10 seconds for 15 times which then was 
repeated three times every ten minutes over the prefrontal cortex conditions a dopamine 
release in the striatum. Still, in a series with 22 patients who each underwent single sessions 
of 0.5 Hz rTMS, 10 Hz rTMS, iTBS, cTBS and sham stimulation no significant effect of either 
stimulation was found on the UPDRS III while training effects may have masked any 
possible therapeutic effect of the TMS (Rothkegel et al, 2009). In accordance with this result, 
the most recent studies evaluating the clinical effectiveness of cTBS or iTBS both of which 
are powerful techniques for the modulation of cortical plasticity in healthy individuals did 
fail to demonstrate a significant therapeutic benefit further suggesting a lack of change in 
cortical excitability in patients with PD (Eggers et al., 2010; Benninger et al., 2011).  
 
Authors Year Verum Sham 
No. Of 
ses. 
Coil Hz Sec dd RMT n Method Results 
Shimam
oto et al. 
2001 
Bilateral 
frontal 
cortex 
Acoustic sham 
8 (once 
a week)
Round 0.2 300 On
100 
±10%
9 
1(150s 
left+150s 
right) 
Mild but significant 
improvement of UPDRS III 
after 2 months. No 
improvement after 1 
month. Significant effect on 
activities of daily living. 
Ikeguchi 
et al. 
2003 
F3 
(clockwise) 
or F4 
(counterclo
ckwise) 
Occipital 
stimulation between 
inion and auditory 
meatus (clockwise 
on the left, 
counterclockwise on 
the right) 
6 in 2 
weeks
Round 0.2 600 On
70% of 
max. 
output
12
1(150s 
left+300s 
Pause(?)
+150s 
right) 
Mild but significant 
decrease of UPDRS III in 
up to 7 days after rTMS 
Okabe et 
al. 
2003 
Motor 
cortex 
Sham condition + 
occipital lobe 
8 (once 
a week)
Round 0.2 500 On
110% 
AMT
85
1(250s 
clockwis
e-250s 
anticlock
wise) 
No sigificant effect on 
UPDRS 
Lefauche
ur et al. 
2004 M1(hand) Sham coil 1 F8 0.5 
120
0 
Off 80% 12
continuo
us 
Significant decrease in 
UPDRS equal to 28-32% of 
the l-dopa effect 
Arias et 
al. 
2010 Vertex 
Two coils (inactive 
coils beneath an 
active coil 
10 Round 1 100 On 90% 9 
1(50s 
clockwis
e-5min 
pause-
50s 
anticlock
wise) 
No significant effects on 
any signs compared to 
placebo stimulation 
Eggers et 
al. 
2010 M1(hand)
Same coil placed 90° 
in angulation over 
M1 
1 F8 50/5 40 Off
80%A
MT 
8 1(40s) 
No significant effect on 
UPDRS III nor measures of 
cortical excitability 
Table 2. Studies on the therapeutic use of low-frequency rTMS in patients with PD. Study-
results reported here mainly refer to the UPDRS while other measures of motor excitability 
are mainly neglected. M1 = primary motor cortex, no. of ses. = number of sessions, F8 = 
figure of eight, Hz = Hertz, dd = dopaminergic drugs during stimulation, RMT = resting 
motor threshold, AMT = active motor threshold, DLPFC = dorsolateral prefrontal cortex, 
mA = milli Ampere, UPDRS = unified Parkinson’s disease rating scale.  
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Authors Year Verum Sham 
No. Of 
ses. 
Coil Hz Sec dd RMT n Method Results 
Siebner 
et al. 
2000 M1(hand) Midfrontal 1 F8 5 600 Off 90% 10
15(30 s 
stimulati
on + 10 s 
pause)
Significant decrease in 
UPDRS III 1 h after 
stimulation 
Khedr et 
al. 
2003 
Lower 
limbs+M1(
hand l+r)
Same condition, 
elevated+angled 
away from head 
10 
(conse
cutive 
days)
F8 5 400 Off 120% 36
200 s 
over 
lower 
limbs + 
100s 
each 
over left 
and 
right 
hand 
Significant decrease in 
UPDRS 1h after 1th, 5th, 
10th stimulation and after 
one month 
Lefauche
ur et al. 
2004 M1(hand) Sham coil 1 F8 10 
120
0 
Off 80% 12
20(10s 
stimulati
on+50s 
pause)
Significant decrease in 
UPDRS equal to 28-32% of 
the l-dopa effect 
Lomarev 
et al. 
2006 
M1(hand) 
+ DLPFC 
each left 
and right
Verum coil turned  
around 180° 
8 
(within 
4 
weeks)
Solid 
core 
coil 
25 
120
0 
On 100% 8+8
4(12s) 
each on 
left+righ
t M1, 
left+righ
t DLPFC
No significant effect on 
UPDRS; Significant 
improvement in other 
motor tests. 
Del 
Olmo et 
al. 
2007 DLPFC 
Verum coil 7 cm 
rostrally to the 
vertex 
10 F8 10 
180
0 
On 90% 8+5
3(15(1s 
stimulati
on +10s 
pause)) 
separate
d by 10 
min. 
No significant change in 
UPDRS after stimulation. 
Significant improvement of 
other motor tests. 
Benning
er et al. 
2011 
M1(hand) 
+ DLPFC 
each left 
and right
Sham coil 8 
Solid 
core
50/5 190 On
80%A
MT 
13+
13
20(2s 
TBS+8s 
pause)
No significant effect on 
UPDRS III; significant 
effect on mood 
Table 3. Studies on the therapeutic use of high-frequency rTMS in patients with PD. Study-
results reported here mainly refer to the UPDRS while other measures of motor excitability 
are mainly neglected.M1 = primary motor cortex, no. of ses. = number of sessions, F8 = 
figure of eight, Hz = Hertz, dd = dopaminergic drugs during stimulation, RMT = resting 
motor threshold, AMT = active motor threshold, TBS = theta burst stimulation, DLPFC = 
dorsolateral prefrontal cortex, mA = milli Ampere, UPDRS = unified Parkinson’s disease 
rating scale.  
Transcranial direct current stimulation:  
There are few studies in which the therapeutic efficiency of tDCS in PD was investigated 
(Table 4). An improvement of motor function in patients with PD measured by the 
UPDRS after 20 minutes anodal but not cathodal tDCS over the M1 region has been 
reported (Fregni et al., 2006). Boggio et al. (2006) demonstrated that patients with PD 
performed better in a memory and alertness test during a left prefrontal tDCS than during 
sham-stimulation. In another study the technique of rTMS was combined with tDCS in 
order to improve bradykinesia in PD (Grüner et al., 2010). In this study low frequency 
rTMS over the primary motor cortex contralateral to the more effected upper extremity 
was preceded by either sham, cathodal or anodal tDCS. Whereas the results in different 
tests of movement control (frequency of finger and hand tapping, horizontal pointing 
movements) improved significantly after performing rTMS preceded by either sham or 
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anodal tDCS the beneficial effect of 1 Hz rTMS on bradykinesia was reduced when 
preconditioning was performed with cathodal tDCS. Patients were tested while they were 
on dopaminergic drugs in this study as well. In the most recent study 25 participants with 
PD received 20 minutes of 2 mA anodal tDCS over the (pre)motor or prefrontal cortex on 
8 days within 2.5 weeks each while on parkinsonian medication. A significant clinical 
improvement of the mobility of the upper extremity in the on- and off-state one day after 
the last stimulation was the main result in this study. But neither the velocity of gait nor 
the overall UPDRS score differed between sham and verum stimulation (Benninger et al., 
2010). Also, there was a significant placebo effect in most conditions. However, size and 
montage of the electrodes used in this study differed from previous attempts possibly 
confounding the comparability of these results to earlier approaches and studies in 
healthy individuals. Finally, techniques of transcranial electrical stimulation may be able 
to improve symptoms of PD even though current data indicate that the effect size may be 
moderate. Development of new stimulation protocols may improve understanding of 
pathophysiological concepts of PD and increase therapeutic efficacy (Pogosyan et al., 
2009; Moliadze et al., 2010).  
 
Authors Year Location Conditions mA Min dd n Object Results 
Fregni et 
al. 
2006 
M1 
DLPFC 
Anodal/cathodal  1 20 Off 8/9
Motor 
performance 
Significant improvement of UPDRS 
III (about 22% reduction) only after 
anodal stimulation of M1 
Boggio 
et al. 
2006 
LDLPFC 
M1 
Anodal/Sham 
Anodal/Sham 
 
1 vs. 2 20 Off 9 
Working 
memory 
Significant improvement of 
working memory only with 2mA 
anodal stimulation of the LDLPFC 
Grüner 
et al. 
2010 M1 
Anodal/Cathodal/
Sham 
1 10 On 15 
Motor 
performance 
Significant improvement of motor 
performance (hand tapping and 
horizontal pointing frequency) 
after 1 Hz rTMS preconditioned by 
anodal or sham tDCS  
Benning
er et al. 
2010 
M1/M2 + 
Prefront. 
cortex 
Anodal/Sham 2 20 On 25 
Gait + hand 
and arm 
movements 
Improvement of upper extremity 
bradykinesia 1 day after anodal 
stimulation 
Table 4. Summary of the therapeutic studies of transcranial direct current stimulation (tDCS) 
in Parkinson’s disease. M1 = primary motor cortex, M2 = premotor cortex, LDLPFC = left 
dorsolateral prefrontal cortex, mA = milli Ampere, UPDRS = unified Parkinson’s disease 
rating scale. 
3. Conclusion 
Electrical or magnetic stimulation techniques amend the therapeutic tools for the treatment 
of PD. Among them, deep brain stimulation is the only approved treatment. It’s positive 
effect on tremor and bradykinesia is significant and immediate in patients with advanced 
PD. In contrast, rTMS and tDCS are experimental techniques and their therapeutic effects, if 
present, are comparably small. Still, these techniques are relatively new and future protocols 
may improve their efficacy.  
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